1,4-dihydropyridine compounds, pharmaceutical compositions,...

Details 1,4-dihydropyridine compounds, pharmaceutical compositions,... 1,4-dihydropyridine compounds, pharmaceutical compositions,...

2004-11-03

2009-02-03

Davis, Zinna N (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S336000, C514S340000, C514S341000, C546S268100, C546S268400, C546S286000

Reexamination Certificate

active

07485653

ABSTRACT:
The present invention provides certain substituted 1,4-dihydropyridine compounds, including pure enantiomeric forms and pharmaceutical formulations thereof. These compounds provide for elevation of α-MyHC protein levels and α-MyHC mRNA levels, and most frequently these same compounds provide simultaneous lowering of β-MyHC protein levels and β-MyHC mRNA levels. Thus, these compounds may be used alone or in conjunction with other drugs to treat heart failure.

REFERENCES:
patent: 5604251 (1997-02-01), Heitsch et al.
patent: 0273349 (1988-07-01), None
patent: WO 98/33791 (1994-05-01), None
patent: WO 03/062201 (2003-07-01), None
patent: WO 03/088970 (2003-10-01), None
Eichhorn and Bristow, “Medical Therapy Can Improve the Biological Propreties of the Chonically Failing Heart: A New Era in the Treatment of Heart Failure,”Circulation, 94:2285-2296, 1996.
Hajjar et al., “Cross-Bridge Dynamics in Human Ventricular Myocardium: Regulation of Contractility in the Failing Heart,”Circulation, 86(6):1819-1826, 1992.
Krauze and Duburs, “Synthesis and Properties of 3-Cyano-4-(4-Cyanophenyl)-1,4-Dihydropyridine-2(3H)-Thiones,”Chemistry of Heterocyclic Compounds, 36:693-697, 2000.
Krauze et al., “Efficient Regioselective One-pot Synthesis of Partially Hydrogenated Thiazolo [3,2-a]pyridines,”Tetrahedron, 54:9161-9168, 1998.
Krauze et al., “Synthesis and cardiovascular activity of 4-substituted 2-alkythio-1,4-dihydropyridines,”Khimiko-Farmatsevticheskii Zhurnal, 22: 955-959, 1988.
Krauze et al., “Cimg id="CUSTOM-CHARACTER-00001" he="2.46mm" wi="1.44mm" file="US07485653-20090203-P00001.TIF" alt="custom character" img-content="character" img-format="tif" ?HTE3img id="CUSTOM-CHARACTER-00002" he="2.46mm" wi="1.44mm" file="US07485653-20090203-P00001.TIF" alt="custom character" img-content="character" img-format="tif" ?img id="CUSTOM-CHARACTER-00003" he="2.46mm" wi="1.44mm" file="US07485653-20090203-P00001.TIF" alt="custom character" img-content="character" img-format="tif" ?MMimg id="CUSTOM-CHARACTER-00004" he="2.46mm" wi="1.78mm" file="US07485653-20090203-P00002.TIF" alt="custom character" img-content="character" img-format="tif" ?HOTPOimg id="CUSTOM-CHARACTER-00005" he="2.46mm" wi="2.12mm" file="US07485653-20090203-P00003.TIF" alt="custom character" img-content="character" img-format="tif" ?HAimg id="CUSTOM-CHARACTER-00006" he="2.46mm" wi="1.78mm" file="US07485653-20090203-P00004.TIF" alt="custom character" img-content="character" img-format="tif" ?AKTimg id="CUSTOM-CHARACTER-00007" he="2.46mm" wi="1.44mm" file="US07485653-20090203-P00001.TIF" alt="custom character" img-content="character" img-format="tif" ?BHOCimg id="CUSTOM-CHARACTER-00008" he="2.46mm" wi="5.67mm" file="US07485653-20090203-P00005.TIF" alt="custom character" img-content="character" img-format="tif" ?POimg id="CUSTOM-CHARACTER-00009" he="2.79mm" wi="2.12mm" file="US07485653-20090203-P00006.TIF" alt="custom character" img-content="character" img-format="tif" ?3BOimg id="CUSTOM-CHARACTER-00010" he="2.46mm" wi="5.67mm" file="US07485653-20090203-P00007.TIF" alt="custom character" img-content="character" img-format="tif" ?IX Timg id="CUSTOM-CHARACTER-00011" he="2.46mm" wi="1.44mm" file="US07485653-20090203-P00001.TIF" alt="custom character" img-content="character" img-format="tif" ?A30img id="CUSTOM-CHARACTER-00012" he="2.46mm" wi="2.12mm" file="US07485653-20090203-P00003.TIF" alt="custom character" img-content="character" img-format="tif" ?O [3,2]-img id="CUSTOM-CHARACTER-00013" he="2.46mm" wi="1.78mm" file="US07485653-20090203-P00008.TIF" alt="custom character" img-content="character" img-format="tif" ?EH3img id="CUSTOM-CHARACTER-00014" he="2.46mm" wi="1.44mm" file="US07485653-20090203-P00001.TIF" alt="custom character" img-content="character" img-format="tif" ?Mimg id="CUSTOM-CHARACTER-00015" he="2.46mm" wi="1.44mm" file="US07485653-20090203-P00001.TIF" alt="custom character" img-content="character" img-format="tif" ?img id="CUSTOM-CHARACTER-00016" he="2.46mm" wi="5.67mm" file="US07485653-20090203-P00009.TIF" alt="custom character" img-content="character" img-format="tif" ?A3Oimg id="CUSTOM-CHARACTER-00017" he="2.46mm" wi="1.78mm" file="US07485653-20090203-P00008.TIF" alt="custom character" img-content="character" img-format="tif" ?A,”Khimiko-Farmatsevticheskii Zhurnal, 25;40-42, 1991 (English Abstract).
Krauze et al., “Cimg id="CUSTOM-CHARACTER-00018" he="2.46mm" wi="1.44mm" file="US07485653-20090203-P00001.TIF" alt="custom character" img-content="character" img-format="tif" ?HTE3, CBOimg id="CUSTOM-CHARACTER-00019" he="2.79mm" wi="2.12mm" file="US07485653-20090203-P00006.TIF" alt="custom character" img-content="character" img-format="tif" ?CTBAimg id="CUSTOM-CHARACTER-00020" he="2.46mm" wi="1.44mm" file="US07485653-20090203-P00001.TIF" alt="custom character" img-content="character" img-format="tif" ?KAPimg id="CUSTOM-CHARACTER-00021" he="2.46mm" wi="2.12mm" file="US07485653-20090203-P00003.TIF" alt="custom character" img-content="character" img-format="tif" ?img id="CUSTOM-CHARACTER-00022" he="2.46mm" wi="1.44mm" file="US07485653-20090203-P00001.TIF" alt="custom character" img-content="character" img-format="tif" ?OBACKYimg id="CUSTOM-CHARACTER-00023" he="2.46mm" wi="2.12mm" file="US07485653-20090203-P00003.TIF" alt="custom character" img-content="character" img-format="tif" ?img id="CUSTOM-CHARACTER-00024" he="2.46mm" wi="1.78mm" file="US07485653-20090203-P00004.TIF" alt="custom character" img-content="character" img-format="tif" ?PHAimg id="CUSTOM-CHARACTER-00025" he="2.46mm" wi="1.78mm" file="US07485653-20090203-P00004.TIF" alt="custom character" img-content="character" img-format="tif" ?AKTimg id="CUSTOM-CHARACTER-00026" he="2.46mm" wi="1.44mm" file="US07485653-20090203-P00001.TIF" alt="custom character" img-content="character" img-format="tif" ?BHOCTimg id="CUSTOM-CHARACTER-00027" he="2.46mm" wi="1.78mm" file="US07485653-20090203-P00010.TIF" alt="custom character" img-content="character" img-format="tif" ?3AMEimg id="CUSTOM-CHARACTER-00028" he="2.46mm" wi="2.79mm" file="US07485653-20090203-P00011.TIF" alt="custom character" img-content="character" img-format="tif" ?EHHimg id="CUSTOM-CHARACTER-00029" he="2.46mm" wi="1.78mm" file="US07485653-20090203-P00010.TIF" alt="custom character" img-content="character" img-format="tif" ?IX 4-img id="CUSTOM-CHARACTER-00030" he="2.46mm" wi="5.67mm" file="US07485653-20090203-P00009.TIF" alt="custom character" img-content="character" img-format="tif" ?img id="CUSTOM-CHARACTER-00031" he="2.46mm" wi="1.44mm" file="US07485653-20090203-P00001.TIF" alt="custom character" img-content="character" img-format="tif" ?img id="CUSTOM-CHARACTER-00032" he="2.46mm" wi="5.67mm" file="US07485653-20090203-P00009.TIF" alt="custom character" img-content="character" img-format="tif" ?img id="CUSTOM-CHARACTER-00033" he="2.46mm" wi="1.44mm" file="US07485653-20090203-P00001.TIF" alt="custom character" img-content="character" img-format="tif" ?POimg id="CUSTOM-CHARACTER-00034" he="2.46mm" wi="1.44mm" file="US07485653-20090203-P00001.TIF" alt="custom character" img-content="character" img-format="tif" ?img id="CUSTOM-CHARACTER-00035" he="2.46mm" wi="5.67mm" file="US07485653-20090203-P00009.TIF" alt="custom character" img-content="character" img-format="tif" ?Pimg id="CUSTOM-CHARACTER-00036" he="2.46mm" wi="1.44mm" file="US07485653-20090203-P00001.TIF" alt="custom character" img-content="character" img-format="tif" ?img id="CUSTOM-CHARACTER-00037" he="2.46mm" wi="5.67mm" file="US07485653-20090203-P00009.TIF" alt="custom character" img-content="character" img-format="tif" ?img id="CUSTOM-CHARACTER-00038" he="2.46mm" wi="1.44mm" file="US07485653-20090203-P00001.TIF" alt="custom character" img-content="character" img-format="tif" ?H-2{3H}-Timg id="CUSTOM-CHARACTER-00039" he="2.46mm" wi="1.44mm" file="US07485653-20090203-P00001.TIF" alt="custom character" img-content="character" img-format="tif" ?OHOB,”Khimiko-Farmatsevticheskii Zhurnal, 22:548-553, 1988 (English Abstract).
Lowes et al., “Changes

Affiliated with

Also associated with

Rating

1,4-dihydropyridine compounds, pharmaceutical compositions,... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 1,4-dihydropyridine compounds, pharmaceutical compositions,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 1,4-dihydropyridine compounds, pharmaceutical compositions,... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4063507